Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Nov 15;128(45):14448-9.
doi: 10.1021/ja064870d.

A functional model for the cysteinate-ligated non-heme iron enzyme superoxide reductase (SOR)

Affiliations

A functional model for the cysteinate-ligated non-heme iron enzyme superoxide reductase (SOR)

Terutaka Kitagawa et al. J Am Chem Soc. .

Abstract

Superoxide reductases (SORs) are cysteine-ligated, non-heme iron enzymes that reduce toxic superoxide radicals (O2-). The functional role of the trans cysteinate, as well as the mechanism by which SOR reduces O2-, is unknown. Herein is described a rare example of a functional metalloenzyme analogue, which catalytically reduces superoxide in a proton-dependent mechanism, via a trans thiolate-ligated iron-peroxo intermediate, the first example of its type. Acetic-acid-promoted H2O2 release, followed by Cp2Co reduction, regenerates the active Fe(II) catalyst. The thiolate ligand and its trans positioning relative to the substrate are shown to contribute significantly to the catalyst's function, by lowering the redox potential, changing the spin state, and dramatically lowering the nuFe-O stretching frequency well-below that of any other reported iron-peroxo, while leaving nuO-O high, so as to favor superoxide reduction and Fe-O, as opposed to O-O, bond cleavage. Thus we provide critical insight into the relationship between the SOR structure and its function, as well as important benchmark parameters for characterizing highly unstable thiolate-ligated iron-peroxo intermediates.

PubMed Disclaimer

Figures

Figure 1
Figure 1
ORTEP of [FeII(cyclam–PrS)]+ (2). Selected bond lengths (Å): Fe–S(1), 2.286(1); Fe–N(1), 2.181(4); Fe–N(2,3,4)avg, 2.16(2).
Figure 2
Figure 2
rRaman spectra of 4 generated from 16O2 (blue), 18O2 (red), and “decayed” product (dashed black) (571 nm excitation @ 183 K in THF/MeOH (upper panel); @ 77K in CH2Cl2/THF/MeOH (lower panel).
Figure 3
Figure 3
Conversion of peroxo–bound 4 (0.5 mM in CH2Cl2) to acetate–bound [FeIII(cyclam–PrS)(OAc)]+ (5) via the addition of HOAc (0.1 equivaliquots every two minutes) at −78 °C.
Figure 4
Figure 4
The catalytic cycle involving [FeII(cyclam–PrS)]+ (2) induced superoxide (O2) reduction

Similar articles

Cited by

References

    1. Kovacs JA. Chem Rev. 2004;104:825–848. - PMC - PubMed
    1. Kurtz DM., Jr Acc Chem Res. 2004;37:902–908. - PubMed
    2. Mathé C, Nivire V, Houée-Levin C, Mattioli TA. Biophys Chem. 2006;119:38–48. - PubMed
    3. Yeh AP, Hu Y, Jenney FE, Jr, Adams MWW, Rees DC. Biochemistry. 2000;39:2499–2508. - PubMed
    4. Emerson JP, Coulter ED, Cabelli DE, Phillips RS, Kurtz DM., Jr Biochemistry. 2002;41:4348–4357. - PubMed
    5. Niviere V, Asso M, Weill CO, Lombard M, et al. Biochemistry. 2004;43:808–818. - PubMed
    6. Mathe C, Mattioli TA, Horner O, Lombard M, Latour J-M, Fontecave M, Niviere V. J Am Chem Soc. 2002;124:4966–4967. - PubMed
    7. Horner O, Oddou J–L, Niviere V, Fontecave M, Halfen JA, Latour J-M, et al. Biochemistry. 2004;43:8815–8825. - PubMed
    8. Mathé C, Nivière V, Mattioli TA. J Am Chem Soc. 2005;127:16436–16441. - PubMed
    9. Clay MD, Jenney FE, Jr, Hagedoorn PL, George GN, Adams MWW, Johnson MK. J Am Chem Soc. 2002;124:788–805. - PubMed
    10. Jovanovic T, Krebs C, Moura I, Moura JJG, Radolf JD, Huynh BH, Rusnak F, et al. J Biol Chem. 2000;275:28439–28448. - PubMed
    1. Gogun Y, Sakurada S, Kimura Y, Nagumo M. J Clin Biochem Nutr. 1990;8:85–92.
    2. Kocaturk PA, Akbostanci MC, Tan F, Kavas GO. Pathophysiology. 2000;7:63–67. - PubMed
    3. Ihara Y, Chuda M, Kuroda S, Hayabara T. J Neurol Sci. 1999;170:90–95. - PubMed
    4. De Leo ME, Borrello S, Passantino M, Palazzotti B, Galeotti T, Masullo C, et al. Neurosci Lett. 1998;250:173–176. - PubMed
    1. Roelfes G, Ho RYN, Rohde J-U, Feringa BL, Munck E, Que L, Jr, et al. Inorg Chem. 2003;42:2639–2653. - PubMed
    2. Shearer J, Scarrow RC, Kovacs JA. J Am Chem Soc. 2002;124:11709–11717. - PubMed
    3. Bolland V, Banse F, Mattioli TA, Blondin G, Girerd JJ, et al. Inorg Chem. 2003;42:2470–2477. - PubMed
    1. Addision AW, Rao TN, Reedijk J. J Chem Soc Dalton Trans. 1984:1349.

Publication types